Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

Recruiting

Phase 3

SurovatamigSurovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

Sponsor:

AstraZeneca

Code:

NCT07509151

Conditions

Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV

Eligibility Criteria

Sex: All

Age: 18

Healthy Volunteers: Not accepted

Interventions

Surovatamig

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-02. This information was provided to ClinicalTrials.gov by AstraZeneca on 2026-06-01.